tipifarnib has been researched along with atorvastatin in 3 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (atorvastatin) | Trials (atorvastatin) | Recent Studies (post-2010) (atorvastatin) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 7,420 | 2,058 | 3,782 |
| Protein | Taxonomy | tipifarnib (IC50) | atorvastatin (IC50) |
|---|---|---|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.0064 | |
| Insulin receptor | Rattus norvegicus (Norway rat) | 0.0002 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.0002 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | 0.0054 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 4.3 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Conney, AH; Cui, XX; Ding, N; Du, Z; Gao, Z; Hu, C; Huang, H; Lin, Y; Rabson, AB; Shih, WJ; Wei, X; Zheng, X | 1 |
| Jones, RD; Li, H; Liao, J; Sun, L; Tong, X; Xu, D; Yang, GY | 1 |
| Chen, J; Goodin, S; Li, DL; Ma, YR; Ma, YY; Ren, X; Wang, X; Xu, XT; Zhang, K; Zhao, DG; Zheng, X; Zhou, RP | 1 |
3 other study(ies) available for tipifarnib and atorvastatin
| Article | Year |
|---|---|
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Female; Heptanoic Acids; Humans; Injections, Intraperitoneal; Mice; Mice, SCID; Neoplasms, Experimental; Pancreatic Neoplasms; Pyrazoles; Pyrroles; Quinolones; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53.
Topics: Animals; Atorvastatin; Carcinogenesis; Cell Line, Tumor; Disease Models, Animal; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; HSP40 Heat-Shock Proteins; Humans; Mice; Molecular Chaperones; Mutant Proteins; Pancreas; Pancreatic Neoplasms; Prenylation; Proto-Oncogene Proteins p21(ras); Quinolones; Tumor Suppressor Protein p53 | 2019 |
Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Quinolones; Signal Transduction; Spheroids, Cellular | 2021 |